/CDXS
CDXS Stock - Codexis, Inc.
Healthcare|BiotechnologyNASDAQ
$1.66+1.22%
+$0.02 (+1.22%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.21
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+562.7%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CDXS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.64 – $1.68
TARGET (TP)$11.00
STOP LOSS$1.53
RISK/REWARD1:71.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.47
52W High$5.51
52W Low$1.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $59.34M | $70.14M | $138.59M | $104.75M | $69.06M |
| Gross Profit | $43.06M | $57.33M | $100.56M | $82.55M | $55.31M |
| Gross Margin | 72.6% | 81.7% | 72.6% | 78.8% | 80.1% |
| Operating Income | $-58,519,000 | $-68,069,000 | $-34,881,000 | $-22,697,000 | $-23,920,000 |
| Net Income | $-65,276,000 | $-76,240,000 | $-33,592,000 | $-21,279,000 | $-24,010,000 |
| Net Margin | -110.0% | -108.7% | -24.2% | -20.3% | -34.8% |
| EPS | $-0.89 | $-1.12 | $-0.51 | $-0.33 | $-0.40 |
Company Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
3
60%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$7
Average Target
↑ 301.6% Upside
Now
$4
Low
$7
Average
$11
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 19th 2024 | The Benchmark Company | Downgrade | Hold | - |
| June 3rd 2024 | Jefferies | Resumed | Buy | $5 |
| May 30th 2024 | Cantor Fitzgerald | Initiation | Overweight | $11 |
| February 29th 2024 | The Benchmark Company | Upgrade | Buy | - |
| November 7th 2023 | The Benchmark Company | Downgrade | Hold | - |
| August 7th 2023 | TD Cowen | Downgrade | Market Perform | $4← $21 |
| May 9th 2023 | H.C. Wainwright | Downgrade | Neutral | - |
Earnings History & Surprises
CDXSBeat Rate
67%
Last 18 quarters
Avg Surprise
+8.1%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.22
Q4 2025
EPS Surprise History
Q1 24
+112.5%
$0.02vs$-0.16
Q2 24
+5.9%
$-0.16vs$-0.17
Q3 24
-23.1%
$-0.32vs$-0.26
Q4 24
-16.0%
$-0.29vs$-0.25
Q1 25
-225.0%
$-0.13vs$-0.04
Q2 25
-25.0%
$-0.25vs$-0.20
Q3 25
+5.9%
$-0.16vs$-0.17
Q4 25
-46.7%
$-0.22vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.01 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.15 | $-0.22 | -46.7% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.20 | $-0.25 | -25.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.04 | $-0.13 | -225.0% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.25 | $-0.29 | -16.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.26 | $-0.32 | -23.1% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.16 | $0.02 | +112.5% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.32 | $-0.26 | +18.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.29 | $-0.34 | -17.2% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.14 | $-0.04 | +71.4% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.09 | $0.03 | +133.3% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.17 | $-0.07 | +58.8% | ✓ BEAT |
Latest News
Codexis shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 7, 2025, 12:17 PM
Codexis shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 6, 2025, 10:05 PM
In October, Codexis Announces Signing Of $37.8M Supply Assurance Agreement with Merck, Reduced Around 24% Of Its Workforce
➖ NeutralBenzinga•Nov 6, 2025, 09:50 PM•Also:
Codexis Q3 EPS $(0.22) Misses $(0.15) Estimate, Sales $8.601M Miss $18.510M Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:23 PM
Codexis And Nitto Denko Avecia Sign Agreement To Evaluate Codexis' ECO Synthesis Manufacturing Platform
📈 PositiveBenzinga•Oct 29, 2025, 02:00 PM
Codexis Revenue Jumps 91 Percent in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 09:17 PM
Frequently Asked Questions about CDXS
What is CDXS's current stock price?
Codexis, Inc. (CDXS) is currently trading at $1.66 per share. The stock has moved +1.22% today.
What is the analyst price target for CDXS?
The average analyst price target for CDXS is $11.00, based on 1 analyst.
What sector is Codexis, Inc. in?
Codexis, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CDXS's market cap?
Codexis, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does CDXS pay dividends?
No, Codexis, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
GNFT
Genfit S.A.
$5.61
Mkt Cap: $0.3B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
IPHA
Innate Pharma S.A.
$1.75
Mkt Cap: $0.1B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
RANI
Rani Therapeutics Holdings, Inc.
$1.51
Mkt Cap: $0.1B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
Explore stocks similar to CDXS for comparison